Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

I-Mab Acquires Bridge Health to Bolster CLDN18.2 Bispecific Program

I-Mab Acquires Bridge Health to Bolster CLDN18.2 Bispecific Program

I-Mab, a Maryland-based biotech company, has announced the acquisition of Bridge Health for $3 million upfront, solidifying its strategic pivot towards the development of givastomig, a CLDN18.2x4-1BB bispecific antibody. This move comes as part of I-Mab's efforts to strengthen its position in the competitive landscape of targeted cancer therapies.

NoahAI News7/18/2025
Sarepta Therapeutics Overhauls Leadership Amid Strategic Pivot

Sarepta Therapeutics Overhauls Leadership Amid Strategic Pivot

Sarepta Therapeutics, a prominent player in the pharmaceutical industry, has announced a significant reorganization of its executive team and corporate strategy. This shake-up comes in the wake of recent setbacks and marks a pivotal moment for the company as it seeks to navigate challenges in its gene therapy program.

NoahAI News7/18/2025
Novartis Halts Ianalumab Development for Hidradenitis Suppurativa, Focuses on Other Indications

Novartis Halts Ianalumab Development for Hidradenitis Suppurativa, Focuses on Other Indications

Novartis, the Swiss pharmaceutical giant, has announced the discontinuation of its ianalumab program for hidradenitis suppurativa following disappointing results in a phase 2 clinical trial. The company, however, remains optimistic about the drug's potential in other indications, particularly Sjögren's disease.

NoahAI News7/18/2025
BrainStorm's NurOwn: ALS Patients Petition FDA for Reconsideration Amid New Survival Data

BrainStorm's NurOwn: ALS Patients Petition FDA for Reconsideration Amid New Survival Data

BrainStorm Cell Therapeutics' journey with its amyotrophic lateral sclerosis (ALS) treatment NurOwn has taken a new turn as patients and advocates push for FDA reconsideration. The stem cell therapy, which faced regulatory setbacks in recent years, is now at the center of a Citizens' Petition backed by compelling survival data from an expanded access program.

NoahAI News7/18/2025
Steward Health Care Sues Former Leadership and Tenet Healthcare Amid Bankruptcy Fallout

Steward Health Care Sues Former Leadership and Tenet Healthcare Amid Bankruptcy Fallout

Steward Health Care, a bankrupt health system, has launched a series of lawsuits against its former leadership and business associates, including Tenet Healthcare, in an attempt to recover funds and address alleged misconduct that contributed to its financial collapse. The legal actions, filed as part of a bankruptcy court-approved plan, aim to claw back millions of dollars to repay the company's substantial debts.

NoahAI News7/18/2025
GSK's Blenrep Faces Setback in FDA Advisory Committee Review

GSK's Blenrep Faces Setback in FDA Advisory Committee Review

GSK's efforts to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. market have encountered a significant obstacle following a negative vote from the FDA's Oncologic Drugs Advisory Committee (ODAC). The committee's decision, based on concerns over ocular toxicity, dosing, and trial demographics, casts doubt on the drug's immediate future in the United States.

NoahAI News7/18/2025
Sarepta Therapeutics Faces Setbacks: Adds Black Box Warning to Elevidys, Announces Major Layoffs

Sarepta Therapeutics Faces Setbacks: Adds Black Box Warning to Elevidys, Announces Major Layoffs

Sarepta Therapeutics, a Cambridge, Massachusetts-based biotech company, has announced significant changes following recent setbacks with its gene therapy treatment for Duchenne muscular dystrophy (DMD). The company is adding a black box warning to Elevidys and restructuring its workforce and pipeline in response to recent patient deaths and regulatory scrutiny.

NoahAI News7/17/2025
Sarepta Therapeutics Announces Major Restructuring Amid Gene Therapy Setbacks

Sarepta Therapeutics Announces Major Restructuring Amid Gene Therapy Setbacks

Sarepta Therapeutics, a leading biopharmaceutical company specializing in genetic medicines for rare diseases, has unveiled a significant restructuring plan following recent setbacks with its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The company's decision to reduce its workforce and refocus its research efforts marks a pivotal moment in the evolving landscape of gene therapy development and commercialization.

NoahAI News7/17/2025
AstraZeneca's Amyloidosis Drug Fails Primary Endpoint in Late-Stage Trials, Shows Promise in Subgroup

AstraZeneca's Amyloidosis Drug Fails Primary Endpoint in Late-Stage Trials, Shows Promise in Subgroup

AstraZeneca's experimental rare disease drug, anselamimab, has failed to meet its primary endpoint in two late-stage clinical trials for light chain amyloidosis. However, the pharmaceutical giant reports a potential benefit in a specific patient subgroup, keeping hopes alive for the treatment's future.

NoahAI News7/17/2025
GT Medical Secures $53M Funding to Advance Brain Tumor Treatment Device

GT Medical Secures $53M Funding to Advance Brain Tumor Treatment Device

GT Medical Technologies has successfully closed a $53 million funding round to support the commercialization and further development of its innovative brain tumor treatment device, GammaTile. The company, which initially raised $37 million in January, has now secured an additional $16 million from new and existing investors to bolster its efforts in expanding U.S. commercial activities and advancing clinical trials.

NoahAI News7/17/2025
Johnson & Johnson Raises 2025 Outlook as Oncology and Neuroscience Drive Q2 Growth

Johnson & Johnson Raises 2025 Outlook as Oncology and Neuroscience Drive Q2 Growth

Johnson & Johnson (J&J) has kicked off the second quarter 2025 pharmaceutical earnings season with a strong performance, reporting a 6% sales growth and raising its full-year sales estimate by $2 billion. The company's success was primarily driven by its oncology and neuroscience divisions, which offset pressures in other areas of the business.

NoahAI News7/17/2025
GSK's Blenrep Faces FDA Scrutiny in Multiple Myeloma Comeback Bid

GSK's Blenrep Faces FDA Scrutiny in Multiple Myeloma Comeback Bid

GSK's antibody-drug conjugate Blenrep (belantamab mafodotin) is facing intense scrutiny from the U.S. Food and Drug Administration (FDA) as the pharmaceutical giant seeks to reintroduce the treatment for relapsed or refractory multiple myeloma. The FDA's concerns, primarily centered on ocular toxicities and dosing issues, come ahead of a crucial advisory committee meeting scheduled for this week.

NoahAI News7/17/2025
«1...121314...67»